Showing results (31-40 of 56) with videos related to
Sort By:
Pageof 6
Anticancer Research|September 12, 2013
Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcomaAn Coosemans, Anke Vanderstraeten, Sandra Tuyaerts, et al.Anticancer Research|December 11, 2013
Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trialAn Coosemans, Anke Vanderstraeten, Sandra Tuyaerts, et al.Journal of Immunological Methods|January 25, 2012
Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigensAn M T Van Nuffel, Sandra Tuyaerts, Daphné Benteyn, et al.Frontiers in Oncology|November 5, 2019
The Controversial Role of PD-1 and Its Ligands in Gynecological MalignanciesOliviero Marinelli, Daniela Annibali, Cristina Aguzzi, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 9, 2024
An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)Rita Trozzi, Sandra Tuyaerts, Daniela Annibali, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 14, 2025
An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study)Rita Trozzi, Sandra Tuyaerts, Daniela Annibali, et al.Journal of Immunology (Baltimore, Md. : 1950)|November 4, 2006
Melan-A/MART-1-specific CD4 T cells in melanoma patients: identification of new epitopes and ex vivo visualization of specific T cells by MHC class II tetramersGilles Bioley, Camilla Jandus, Sandra Tuyaerts, et al.Journal for Immunotherapy of Cancer|September 16, 2022
Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trialJulia Katharina Schwarze, Jens Tijtgat, Gil Awada, et al.Frontiers in Immunology|November 15, 2021
Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic CellsJens Tijtgat, Jolien De Munck, Inès Dufait, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 7, 2009
Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patientsAude Bonehill, An M T Van Nuffel, Jurgen Corthals, et al.Pageof 6